CI
CRSP icon

Corient IA’s CRISPR Therapeutics CRSP Stock Holding History

Corient IA’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$168K Sell
3,540
-460
-12% -$24.3K 0.16% 227
2025
Q4 		$210K Hold
4,000
– – 0.2% 198
2025
Q3 		$259K Sell
4,000
-1,000
-20% -$57.4K 0.19% 201
2025
Q2 		$243K Buy
+5,000
New +$193K 0.14% 255

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corient IA's CRSP Position: Q1 2026 in Review

Corient IA reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q1 2026, selling an estimated $24.3K and leaving 3,540 shares worth $168K. The position accounts for 0.16% of the portfolio, ranked #227.

Corient IA first reported a position in CRSP in Q2 2025 and has held it in 4 quarters since. The position peaked at $259K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Corient IA held 3,540 shares of CRISPR Therapeutics worth $168K as of Q1 2026.
  • Corient IA sold 460 CRISPR Therapeutics shares in Q1 2026, an estimated $24.3K.
  • CRISPR Therapeutics made up 0.16% of Corient IA's portfolio in Q1 2026, its #227 holding.
  • Corient IA first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Corient IA's CRISPR Therapeutics position peaked at $259K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Corient IA's 13F filing for Q1 2026, filed 14 May 2026.